Fourth quarter 2025 net revenue of $333 million
Fourth quarter 2025 International revenue of $51 million,
Fourth quarter 2025 gross profit margin of 49%
Full year operating and free cash flow from continuing operations of
$152 million and $89 million, respectively
STAMFORD, Conn., Feb. 26, 2026 — Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading international provider of consumer products in cannabis, today reported its financial and operating results for the fourth quarter and full year ended December 31, 2025. All financial information is reported in accordance with U.S. generally accepted accounting principles (“U.S. GAAP” or “GAAP”) and is provided in U.S. dollars unless otherwise indicated.
Boris Jordan, Chairman and CEO of Curaleaf, stated, “We closed 2025 with clear momentum, delivering fourth-quarter revenue of $333 million. Revenue increased 5% sequentially and 2% year over year, bolstered by a broad-based return to growth in nearly all of our domestic markets despite a persistently challenging pricing environment. Our international team closed out an impressive year with $51 million in fourth quarter revenue representing 10% sequential growth and 65% year over year revenue growth. Adjusted gross margin expanded to 49%, up 20 basis points from last year as the benefits from productivity gains in our cultivation facilities outweighed price compression. Adjusted EBITDA totaled $69 million, or 21% of sales, inclusive of a 120 basis point drag from international.
For the year, revenue reached $1.27 billion, with adjusted gross margin of 50% and adjusted EBITDA of $275 million, or 22% of revenue. We generated $152 million in operating cash flow and $89 million in free cash flow from continuing operations, while ending the year with $102 million of cash on the balance sheet. These results were delivered despite a third consecutive year of double-digit price compression, underscoring the strength, discipline, and resilience of our operating model and the success of our Return to Our Roots plan.”
Mr. Jordan continued, “With our $500 million debt offering and Return to Our Roots plan now complete, we have reset the foundation of our business, and are transitioning from stabilization to acceleration with our Built for Growth strategy. By leveraging the platform we have strengthened—improved cultivation economics, tighter merchandising discipline, brand-led innovation, and enhanced execution—we are positioned to drive sustainable organic growth augmented by opportunistic acquisitions.”
Fourth Quarter 2025 Financial Highlights
- Net revenue of $333.1 million, a year-over-year increase of 2% compared to Q4 2024 net revenue of $327.9 million. Sequentially, net revenue increased 5% compared to Q3 2025 net revenue of $317.9 million
- Gross profit of $161.8 million and gross profit margin of 49%, an increase of 60 basis points year-over-year
- Adjusted gross profit(1) of $161.9 million and adjusted gross profit margin(1) of 49%, an increase of 20 basis points year-over-year
- Net loss attributable to Curaleaf Holdings, Inc. from continuing operations of $49.3 million or net loss per share from continuing operations of $0.06
- Adjusted net loss(1) from continuing operations of $39.5 million or adjusted net loss(1) per share from continuing operations of $0.05
- Adjusted EBITDA(1) of $69.0 million and adjusted EBITDA margin([1]) of 20.7%, a 250 basis point decrease year-over-year
- Cash at quarter end totaled $101.6 million
- Operating and free cash flow was $42 million and $25 million, respectively
Full Year 2025 Financial Highlights
- Net revenue of $1,268.1 million
- International revenue of $172.5 million, an increase of 63% compared to 2024 revenue of $105.6 million
- Gross profit of $631.0 million and gross margin of 50%
- Adjusted gross profit(1) of $632.5 million and adjusted gross profit margin(1) of 50%
- Operating cash flow from continuing operations of $152.0 million and free cash flow from continuing operations of $89.3 million
- Net loss from continuing operations of $201.9 million or net loss per share from continuing operations of $0.26
- Adjusted net loss(1) from continuing operations of $175.9 million or adjusted net loss per share from continuing operations of $0.23
- Adjusted EBITDA(1) of $274.7 million and adjusted EBITDA margin of 21.7%
|
(1) |
Adjusted EBITDA, adjusted net income (loss), adjusted gross profit and free cash flow are non-GAAP financial measures, and adjusted EBITDA margin, adjusted net income (loss) per share and adjusted gross profit margin are non-GAAP financial ratios, in each case without a standardized definition under U.S. GAAP and which may not be comparable to similar measures used by other issuers. See “Non-GAAP Financial Performance Measures” below for definitions and more information regarding Curaleaf’s use of non-GAAP financial measures and non-GAAP financial ratios. See “Reconciliation of Non-GAAP financial measures” below for a reconciliation of each non-GAAP financial measure used in this press release from the most directly comparable U.S. GAAP financial measure. |
|||||||
Fourth Quarter 2025 Operational Highlights
- Expanded retail presence in Florida to 70 dispensaries with the opening of Curaleaf Cape Canaveral bringing the nationwide total to 159
- Introduced Anthem Bold infused pre-rolls further expanding the Anthem brand portfolio
- Launched six premium flower genetics under our premium flower brand, Dark Heart
- Curaleaf portfolio of brands achieved #1 market share position while Select remained the #1 vape brand in the U.S., according to Hoodie Analytics
- Curaleaf International launched the first medically certified liquid inhalation device, the QMID, in the UK and Germany
Post Fourth Quarter 2025 Operational Highlights
- Expanded retail footprint in Florida to 71 with the opening of Curaleaf Lauderhill
- Opened an adult-use sales dispensary in Bangor, ME bringing the total retail locations to five in the state, and 161 nationwide
- Curaleaf closed on a private placement of non-dilutive 11.5% senior secured notes due February 18, 2029, for aggregate gross proceeds of $500.0 million, which were used to fully repay the outstanding December 2026 note. In conjunction with the new offering, the maturity of the Amended Needham LOC was extended to February 18, 2029 and the interest rate increased from 7.99% to 8.99%, in accordance with the existing terms of the Amended and Restated Needham Loan Agreement.
|
Revenues, net by Segment |
|||||
|
Three Months Ended |
|||||
|
December 31, 2025 |
September 30, 2025 |
December 31, 2024 |
|||
|
Domestic: |
|||||
|
Retail revenue |
$ 221,221 |
$ 211,483 |
$ 235,697 |
||
|
Wholesale revenue |
61,167 |
60,136 |
61,146 |
||
|
Management fee income |
23 |
245 |
363 |
||
|
Total revenues, net – Domestic |
$ 282,411 |
$ 271,864 |
$ 297,206 |
||
|
Three Months Ended |
|||||
|
December 31, 2025 |
September 30, 2025 |
December 31, 2024 |
|||
|
International: |
|||||
|
Retail revenue |
$ 15,711 |
$ 14,152 |
$ 11,704 |
||
|
Wholesale revenue |
29,716 |
27,762 |
17,636 |
||
|
Management fee income |
5,230 |
4,078 |
1,333 |
||
|
Total revenues, net – International |
$ 50,657 |
$ 45,992 |
$ 30,673 |
||
|
Years ended December 31, |
|||
|
2025 |
2024 |
||
|
Domestic: |
|||
|
Retail revenue |
$ 868,732 |
$ 994,715 |
|
|
Wholesale revenue |
226,334 |
232,491 |
|
|
Management fee income |
591 |
1,543 |
|
|
Total revenues, net – Domestic |
$ 1,095,657 |
$ 1,228,749 |
|
|
Years ended December 31, |
|||
|
2025 |
2024 |
||
|
International: |
|||
|
Retail revenue |
$ 53,850 |
$ 38,047 |
|
|
Wholesale revenue |
105,905 |
63,078 |
|
|
Management fee income |
12,723 |
4,425 |
|
|
Total revenues, net – International |
$ 172,478 |
$ 105,550 |
|
Balance Sheet and Cash Flow
As of December 31, 2025, the Company had $101.6 million of cash and $548.7 million of outstanding debt, net of unamortized debt discounts and deferred financing fees.
During the year ended December 31, 2025, Curaleaf invested $63.4 million in capital expenditures, focused on facility upgrades, automation and selective retail expansion in strategic markets.
Shares Outstanding
The Company’s weighted average shares outstanding was 771,850,664 and 748,936,695 for the fourth quarter of 2025 and 2024, respectively.
The Company’s weighted average shares outstanding was 762,090,951 and 740,825,099 for the years ended December 31, 2025 and 2024, respectively.
Conference Call Information
The Company will host a conference call and audio webcast for investors and analysts on Thursday, February 26, 2026 at 5:00 P.M. ET to discuss Q4 2025 earnings results. The call can be accessed by dialing 1-844-512-2926 in North America or internationally at 1-412-317-6300. The conference pin # is 3667642.
A replay of the conference call can be accessed at 1-855-669-9658 in North America or internationally at 1-412-317-0088, using the replay pin # 1190273.
A webcast of the call can be accessed on the investor relations section of the Curaleaf website at ir.curaleaf.com. The teleconference will be available for replay starting at approximately 7:00 P.M. ET on Thursday, February 26, 2026 and will end at 11:59 P.M. ET on March 5, 2026.
Non-GAAP Financial and Performance Measures
Curaleaf reports its financial results in accordance with U.S. GAAP and also uses certain non-GAAP financial measures and ratios to evaluate performance. These measures, which include “adjusted gross profit,” “adjusted gross profit margin,” “adjusted net income (loss),” “adjusted EBITDA,” “adjusted EBITDA margin,” and “free cash flow from operations,” do not have standardized definitions under U.S. GAAP and may not be comparable to similar measures used by other issuers.
Curaleaf defines these non-GAAP measures as follows:
- Adjusted gross profit: gross profit net of related add-backs.
- Adjusted gross profit margin: adjusted gross profit divided by total revenues, net.
- Adjusted net income (loss): net income (loss) net of impairment losses (recoveries) and related add-backs.
- Adjusted net income (loss) per share: adjusted net income (loss) divided by the weighted average common shares outstanding.
- Adjusted EBITDA: income (loss) before interest, taxes, depreciation and amortization, net of impairment losses (recoveries), share-based compensation expense and related add-backs.
- Adjusted EBITDA margin: adjusted EBITDA divided by total revenues, net.
- Free cash flow from operations: net cash provided by operating activities from continuing operations, net of purchases and disposals of property, plant and equipment.
Management believes these measures (i) provide investors with additional insight into the Company’s financial strength and underlying performance, (ii) align external reporting with how management evaluates results and (iii) facilitate comparisons with other issuers. These measures should not be considered in isolation from, or as a substitute for, U.S. GAAP results nor should they be considered as indicators of the Company’s future performance. Reconciliations to the most directly comparable U.S. GAAP measures are provided in the accompanying tables.
|
Reconciliation of Non-GAAP financial measures Adjusted Gross Profit from Continuing Operations ($ thousands) |
|||||
|
Three Months Ended |
|||||
|
December 31, 2025 |
September 30, 2025 |
December 31, 2024 |
|||
|
Gross profit from continuing operations |
$ 161,795 |
$ 160,576 |
$ 157,460 |
||
|
Other add-backs(1) |
59 |
216 |
1,324 |
||
|
Adjusted gross profit from continuing operations(2) |
$ 161,854 |
$ 160,792 |
$ 158,784 |
||
|
Adjusted gross profit margin from continuing operations(2) |
48.6 % |
50.6 % |
48.4 % |
||
|
(1) |
For the fourth quarter of 2025, Other add-backs primarily consisted of cost of goods sold associated with inventory and overhead. For the fourth quarter of 2024, Other add-backs primarily consisted of various non-recurring and/or non-routine transactions to cost of goods sold related to severance, inventory adjustments and facility-related expenses. |
|||||
|
(2) |
Represents a Non-GAAP measure or Non-GAAP ratio. See “Non-GAAP Financial and Performance Measures” section of this press release for definitions and more information regarding Curaleaf’s use of Non-GAAP financial measures and Non-GAAP ratios. The table above provides a reconciliation of Gross profit from continuing operations, the most comparable GAAP measure, to Adjusted gross profit from continuing operations, a non-GAAP measure. |
|||||
Gross profit from continuing operations was $161.8 million in the fourth quarter of 2025, compared with $157.5 million in the prior-year period. On an adjusted basis, gross profit from continuing operations was $161.9 million compared with $158.8 million in the prior-year period, and adjusted gross profit margin from continuing operations was 48.6%, compared with 48.4% in the prior-year period, an increase of 20 basis points.
|
Years Ended |
|||
|
December 31, 2025 |
December 31, 2024 |
||
|
Gross profit from continuing operations |
$ 631,022 |
$ 640,777 |
|
|
Other add-backs(1) |
1,487 |
5,260 |
|
|
Adjusted gross profit from continuing operations(2) |
$ 632,509 |
$ 646,037 |
|
|
Adjusted gross profit margin from continuing operations(2) |
49.9 % |
48.4 % |
|
|
(1) |
For the year ended December 31, 2025, Other add-backs primarily consisted of cost of good sold associated with inventory, overhead and labor. For the year ended December 31, 2024, Other add-backs primarily consisted of various non-recurring and/or non-routine transactions to cost of goods sold related to severance, inventory adjustments and facility-related expenses. |
|||
|
(2) |
Represents a Non-GAAP measure or Non-GAAP ratio. See “Non-GAAP Financial and Performance Measures” section of this press release for definitions and more information regarding Curaleaf’s use of Non-GAAP financial measures and Non-GAAP ratios. The table above provides a reconciliation of Gross profit from continuing operations, the most comparable GAAP measure, to Adjusted gross profit from continuing operations, a non-GAAP measure. |
|||
Gross profit from continuing operations was $631.0 million in the year ended December 31, 2025, compared with $640.8 million in the prior-year period. On an adjusted basis, gross profit from continuing operations was $632.5 million, compared with $646.0 million in the prior-year period, and adjusted gross profit margin from continuing operations was 49.9%, compared with 48.4% in the prior-year period, an increase of 150 basis points.
|
Adjusted Net Loss from Continuing Operations ($ thousands) |
|||||
|
Three Months Ended |
|||||
|
December 31, 2025 |
September 30, 2025 |
December 31, 2024 |
|||
|
Net loss from continuing operations |
$ (49,341) |
$ (51,654) |
$ (70,474) |
||
|
Loss on impairment |
5,745 |
848 |
55,790 |
||
|
Other add-backs(1)(3) |
4,122 |
5,500 |
28,326 |
||
|
Adjusted net (loss) income from continuing operations(2) |
$ (39,474) |
$ (45,306) |
$ 13,642 |
||
|
Adjusted net (loss) income per share from continuing operations(2) |
$ (0.05) |
$ (0.06) |
$ 0.02 |
||
|
Weighted average common shares outstanding – basic and diluted |
771,850,664 |
764,825,622 |
748,936,695 |
||
|
(1) |
For the fourth quarter of 2025, Other add-backs primarily consisted of costs related to legal fees and lobbying costs. For the fourth quarter of 2024, Other add-backs primarily consisted of costs related to salaries and benefits, accounting, legal and professional fees and cost of good sold. |
|||||||
|
(2) |
Represents a Non-GAAP measure or Non-GAAP ratio. See “Non-GAAP Financial and Performance Measures” section of this press release for definitions and more information regarding Curaleaf’s use of Non-GAAP financial measures and Non-GAAP ratios. The table above provides a reconciliation of Net loss from continuing operations, the most comparable GAAP measure, to Adjusted net loss from continuing operations, a non-GAAP measure. |
|||||||
|
(3) |
For the three months ended December 31, 2024, other add-backs included $23.5 million of accelerated amortization related leases that were partially abandoned during the period. |
|||||||
|
Years Ended |
|||
|
December 31, 2025 |
December 31, 2024 |
||
|
Net loss from continuing operations |
$ (201,903) |
$ (211,609) |
|
|
Loss on impairments |
9,080 |
54,245 |
|
|
Other add-backs(1)(3) |
16,882 |
44,886 |
|
|
Adjusted net loss from continuing operations(2) |
$ (175,941) |
$ (112,478) |
|
|
Adjusted net loss per share from continuing operations(2) |
$ (0.23) |
$ (0.15) |
|
|
Weighted average common shares outstanding – basic and diluted |
762,090,951 |
740,825,099 |
|
|
(1) |
For the year ended December 31, 2025, Other add-backs primarily consisted of costs related to legal fees, non-routine severance, rent and other facility costs and license fees and excise taxes. For the year ended December 31, 2024, Other add-backs primarily consisted of costs related to salaries and benefits, cost of goods sold, accounting, legal and professional fees and lobbyist/PR spend. |
|||
|
(2) |
Represents a Non-GAAP measure or Non-GAAP ratio. See “Non-GAAP Financial and Performance Measures” section of this press release for definitions and more information regarding Curaleaf’s use of Non-GAAP financial measures and Non-GAAP ratios. The table above provides a reconciliation of Net loss from continuing operations, the most comparable GAAP measure, to Adjusted net loss from continuing operations, a non-GAAP measure. |
|||
|
(3) |
For the year ended December 31, 2024, other add-backs included $23.5 million of accelerated amortization related leases that were partially abandoned during the period. |
|||
|
Adjusted EBITDA ($ thousands) |
|||||
|
Three Months Ended |
|||||
|
December 31, 2025 |
September 30, 2025 |
December 31, 2024 |
|||
|
Net loss |
$ (57,617) |
$ (56,684) |
$ (78,473) |
||
|
Net loss from discontinued operations |
(8,276) |
(5,030) |
(7,999) |
||
|
Net loss from continuing operations |
(49,341) |
(51,654) |
(70,474) |
||
|
Interest expense, net |
24,324 |
25,214 |
24,170 |
||
|
Provision (benefit) for income taxes |
25,215 |
30,236 |
(5,795) |
||
|
Depreciation and amortization(1) |
49,622 |
48,992 |
74,441 |
||
|
Share-based compensation |
12,341 |
10,294 |
5,327 |
||
|
Loss on impairment |
5,745 |
848 |
55,790 |
||
|
Total other (income) expense, net |
(3,026) |
2,277 |
(12,041) |
||
|
Other add-backs(2) |
4,122 |
5,500 |
4,826 |
||
|
Adjusted EBITDA(3) |
$ 69,002 |
$ 71,707 |
$ 76,244 |
||
|
Adjusted EBITDA Margin(3) |
20.7 % |
22.6 % |
23.3 % |
||
|
(1) |
Depreciation and amortization includes amounts charged to Cost of goods sold on the Statement of Operations. |
|||||
|
(2) |
For the fourth quarter of 2025, Other add-backs primarily consisted of costs related to legal fees and lobbying costs. For the fourth quarter of 2024, Other add-backs primarily consisted of costs related to salaries and benefits, accounting, legal and professional fees and cost of good sold. |
|||||
|
(3) |
Represents a Non-GAAP measure or Non-GAAP ratio. See “Non-GAAP Financial and Performance Measures” section of this press release for definitions and more information regarding Curaleaf’s use of Non-GAAP financial measures and Non-GAAP ratios. The table above provides a reconciliation of Net loss, the most comparable GAAP measure, to Adjusted EBITDA, a non-GAAP measure. |
|||||
Adjusted EBITDA was $69.0 million for the fourth quarter of 2025, compared to $76.2 million for the fourth quarter of 2024, and Adjusted EBITDA margin decreased to 20.7%.
|
Years Ended |
|||
|
December 31, 2025 |
December 31, 2024 |
||
|
Net loss |
$ (228,153) |
$ (222,007) |
|
|
Net loss from discontinued operations |
(26,250) |
(10,398) |
|
|
Net loss from continuing operations |
(201,903) |
(211,609) |
|
|
Interest expense, net |
100,166 |
99,840 |
|
|
Provision for income taxes |
123,689 |
98,251 |
|
|
Depreciation and amortization(1) |
196,606 |
231,460 |
|
|
Share-based compensation |
35,736 |
25,696 |
|
|
Loss on impairment |
9,080 |
54,245 |
|
|
Total other income, net |
(5,582) |
(15,984) |
|
|
Other add-backs(2) |
16,882 |
21,386 |
|
|
Adjusted EBITDA(3) |
$ 274,674 |
$ 303,285 |
|
|
Adjusted EBITDA Margin(3) |
21.7 % |
22.7 % |
|
|
(1) |
Depreciation and amortization includes amounts charged to Cost of goods sold on the Statement of Operations. |
|||
|
(2) |
For the year ended December 31, 2025, Other add-backs primarily consisted of costs related to salaries and benefits, accounting, legal and professional fees as well as rent and other facility costs. For the year ended December 31, 2024, Other add-backs primarily consisted of costs related to salaries and benefits, cost of goods sold, accounting, legal and professional fees and lobbyist/PR spend. |
|||
|
(3) |
Represents a Non-GAAP measure or Non-GAAP ratio. See “Non-GAAP Financial and Performance Measures” section of this press release for definitions and more information regarding Curaleaf’s use of Non-GAAP financial measures and Non-GAAP ratios. The table above provides a reconciliation of Net loss, the most comparable GAAP measure, to Adjusted EBITDA, a non-GAAP measure. |
|||
Adjusted EBITDA was $274.7 million in the year ended December 31, 2025, compared with $303.3 million in the prior-year period, and Adjusted EBITDA margin decreased to 21.7%.
|
Free Cash Flow ($ thousands) |
|
|
Year ended |
|
|
December 31, 2025 |
|
|
Net cash provided by operating activities from continuing operations |
$ 152,025 |
|
Less: Purchases of property, plant and equipment, net of disposals |
(62,753) |
|
Free cash flow from continuing operations(1) |
$ 89,272 |
|
(1) |
Represents a Non-GAAP measure or Non-GAAP ratio. See “Non-GAAP Financial and Performance Measures” section of this press release for definitions and more information regarding Curaleaf’s use of Non-GAAP financial measures and Non-GAAP ratios. The table above provides a reconciliation of Net cash provided by operating activities from continuing operations, a GAAP measure, to Free cash flow from continuing operations, a non-GAAP measure. |
||||
|
Condensed Consolidated Balance Sheets ($ thousands) |
|||
|
As of |
|||
|
December 31, 2025 |
December 31, 2024 |
||
|
Assets |
|||
|
Cash and cash equivalents (including restricted cash and cash equivalents) |
$ 101,573 |
$ 107,226 |
|
|
Other current assets |
347,050 |
327,139 |
|
|
Property, plant and equipment, net |
520,386 |
542,604 |
|
|
Right-of-use assets, finance lease, net |
97,599 |
105,168 |
|
|
Right-of-use assets, operating lease, net |
113,274 |
115,829 |
|
|
Intangible assets, net |
1,011,115 |
1,085,397 |
|
|
Goodwill |
635,117 |
628,884 |
|
|
Other long-term assets |
19,201 |
37,461 |
|
|
Total assets |
$ 2,845,315 |
$ 2,949,708 |
|
|
Liabilities, Temporary equity and Shareholders’ equity |
|||
|
Total current liabilities |
$ 294,314 |
$ 387,925 |
|
|
Total long-term liabilities |
1,710,720 |
1,568,390 |
|
|
Redeemable non-controlling interest contingency |
83,931 |
132,179 |
|
|
Total shareholders’ equity |
756,350 |
861,214 |
|
|
Total liabilities, temporary equity and shareholders’ equity |
$ 2,845,315 |
$ 2,949,708 |
|
|
Condensed Consolidated Statements of Operations ($ thousands, except for share and per share amounts) |
|||||||
|
Three months ended December 31, |
Years ended December 31, |
||||||
|
2025 |
2024 |
2025 |
2024 |
||||
|
Revenues, net: |
|||||||
|
Retail and wholesale revenues |
$ 327,815 |
$ 326,182 |
$ 1,254,821 |
$ 1,328,331 |
|||
|
Management fee income |
5,253 |
1,697 |
13,314 |
5,968 |
|||
|
Total revenues, net |
333,068 |
327,879 |
1,268,135 |
1,334,299 |
|||
|
Cost of goods sold |
171,273 |
170,419 |
637,113 |
693,522 |
|||
|
Gross profit |
161,795 |
157,460 |
631,022 |
640,777 |
|||
|
Operating expenses: |
|||||||
|
Selling, general and administrative |
111,149 |
100,511 |
428,442 |
418,534 |
|||
|
Share-based compensation |
12,341 |
5,327 |
35,736 |
25,696 |
|||
|
Depreciation and amortization |
35,388 |
59,972 |
141,394 |
171,804 |
|||
|
Total operating expenses |
158,878 |
165,810 |
605,572 |
616,034 |
|||
|
Income (loss) from continuing operations |
2,917 |
(8,350) |
25,450 |
24,743 |
|||
|
Other income (expense): |
|||||||
|
Interest income |
174 |
176 |
663 |
776 |
|||
|
Interest expense |
(13,569) |
(14,113) |
(56,753) |
(59,353) |
|||
|
Interest expense related to lease liabilities and |
(10,929) |
(10,233) |
(44,076) |
(41,263) |
|||
|
Impairment loss |
(5,745) |
(55,789) |
(9,080) |
(54,245) |
|||
|
Other income, net |
3,026 |
12,040 |
5,582 |
15,984 |
|||
|
Total other expense, net |
(27,043) |
(67,919) |
(103,664) |
(138,101) |
|||
|
Loss before provision for income taxes |
(24,126) |
(76,269) |
(78,214) |
(113,358) |
|||
|
(Provision) benefit for income taxes |
(25,215) |
5,795 |
(123,689) |
(98,251) |
|||
|
Net loss from continuing operations |
(49,341) |
(70,474) |
(201,903) |
(211,609) |
|||
|
Net loss from discontinued operations |
(8,276) |
(7,999) |
(26,250) |
(10,398) |
|||
|
Net loss |
(57,617) |
(78,473) |
(228,153) |
(222,007) |
|||
|
Less: Net income (loss) attributable to non- |
2,200 |
(910) |
2,917 |
(6,584) |
|||
|
Net loss attributable to Curaleaf Holdings, Inc. |
$ (59,817) |
$ (77,563) |
$ (231,070) |
$ (215,423) |
|||
|
Per share – basic and diluted: |
|||||||
|
Net loss per share from continuing operations |
$ (0.06) |
$ (0.09) |
$ (0.26) |
$ (0.29) |
|||
|
Weighted average common shares outstanding – basic |
771,850,664 |
748,936,695 |
762,090,951 |
740,825,099 |
|||
About Curaleaf Holdings
Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf”) is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Anthem, Curaleaf, Find, Grassroots, JAMS, Reef and Select, provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is powered by a strong presence in all stages of the supply chain. Its unique distribution network throughout Europe, Canada and Australasia brings together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.
